PROCEPT BioRobotics Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting third-quarter revenue of $98.3 million and a continued operating loss.

Key Highlights

  • Revenue: $98,291 thousand for the three months ended September 30, 2026, compared to $83,327 thousand in the same period of 2025.
  • Nine-month revenue: $275,922 thousand for the nine months ended September 30, 2026, up from $231,671 thousand in the prior-year period.
  • Operating loss: $(27,376) thousand for the third quarter of 2026, compared to $(23,192) thousand in the third quarter of 2025.
  • Accumulated deficit: $(726,572) thousand as of September 30, 2026, versus $(641,557) thousand at December 31, 2025.
  • Cash and cash equivalents: $218,369 thousand at September 30, 2026, down from $286,503 thousand at December 31, 2025.
  • Shares outstanding: 57,536,121 shares of common stock as of October 29, 2026.
  • Gross profit: $65,148 thousand for Q3 2026, compared to $54,006 thousand in Q3 2025.

PROCEPT BioRobotics Q3 2026 Financial Results and Balance Sheet Position

According to the filing, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) reported revenue of $98,291 thousand for the three months ended September 30, 2026, an increase from $83,327 thousand in the comparable prior-year quarter. For the nine months ended September 30, 2026, the company disclosed revenue of $275,922 thousand, compared to $231,671 thousand for the same period in 2025. Cost of sales for the third quarter was $33,143 thousand, yielding a gross profit of $65,148 thousand.

The filing reported total operating expenses of $92,524 thousand for Q3 2026, consisting of research and development expenses of $20,011 thousand and selling, general and administrative expenses of $72,513 thousand. This produced a loss from operations of $(27,376) thousand for the quarter. Interest expense for the quarter was $(856) thousand, according to the filing. For the nine-month period, the company disclosed a loss from operations of $(87,372) thousand, compared to $(72,818) thousand in the prior-year period.

As of September 30, 2026, the company reported total assets of $473,759 thousand and total liabilities of $144,851 thousand, leaving total stockholders' equity of $328,908 thousand. The accumulated deficit stood at $(726,572) thousand. Long-term debt was reported at $51,767 thousand. The company had 57,439 thousand shares of common stock issued and outstanding as of September 30, 2026, with authorized shares of 300,000 thousand. The filing notes that forward-looking statements contained within the report are subject to the company's cautionary language and known and unknown risks and uncertainties.

What Was Disclosed

PROCEPT BioRobotics filed its quarterly report covering the period ended September 30, 2026, disclosing Q3 revenue of $98,291 thousand, an operating loss of $(27,376) thousand, total assets of $473,759 thousand, and an accumulated deficit of $(726,572) thousand.